海辰药业(300584.SZ)发布上半年业绩，归母净利润2915.77万元，增长17.87%

Core Viewpoint - Haicheng Pharmaceutical (300584.SZ) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue reached 309 million yuan, representing a year-on-year growth of 30.46% [1] - The net profit attributable to shareholders was 29.16 million yuan, showing a year-on-year increase of 17.87% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 28.85 million yuan, reflecting a year-on-year growth of 13.07% [1] - Basic earnings per share were reported at 0.243 yuan [1]